NUCLIDIUM Achieves Patent Milestone for Innovative Cancer Therapies
NUCLIDIUM AG, a pioneering company in clinical-stage radiopharmaceuticals, has made remarkable strides with the recent Notice of Allowance from the U.S. Patent and Trademark Office (USPTO). This pivotal recognition is set to bolster the company's Kalios™ initiative, which focuses on the development of small molecule inhibitors targeting the fibroblast activation protein (FAP). These inhibitors are designed for use alongside various radionuclides, presenting promising options for the diagnosis and treatment of solid tumors.
Kalios™ Program Overview
The Kalios™ program by NUCLIDIUM employs a unique approach that harnesses the targeting capabilities of FAP inhibitors paired with specific copper radioisotopes. Copper-61 is utilized for diagnostic purposes, allowing healthcare professionals to identify tumors effectively, while Copper-67 is poised for therapeutic interventions. This strategic combination is currently being refined to address specific breast and lung cancer cases, marking a significant advancement in the field.
Implications of the Patent Allowance
Receiving the Notice of Allowance signals a monumental milestone for NUCLIDIUM. Leila Jaafar, PhD, CEO and Co-Founder of NUCLIDIUM, articulated the importance of this achievement, noting that it not only strengthens their foothold in a competitive landscape but also highlights the innovative nature of their research. The patent is expected to provide extensive coverage for their existing and future therapeutic products within the Kalios™ framework.
The Significance of FAP in Cancer Diagnosis and Treatment
FAP is increasingly recognized for its potential in cancer management. As a serine protease prevalent in epithelial tumors, FAP is expressed in a high percentage of cancer cases, particularly on cancer-associated fibroblasts. This makes it an optimal target for diagnostics and treatment methods. Current FAP-targeted agents have limitations due to their short half-lives and restricted use in imaging smaller metastases. NUCLIDIUM's innovative compounds are designed to tackle these challenges effectively.
Research and Collaborations Enhancing Drug Development
In a recent preclinical study published in a notable journal, NUCLIDIUM demonstrated the promising attributes of its copper-based FAP-targeting PET radiotracers. The results indicated that their [61Cu]Cu-Kalios PET radioligands exhibit favorable characteristics such as efficient tumor uptake and exceptional tumor-to-background ratios, particularly when utilizing delayed imaging protocols. Such advancements point to the transformative potential of their copper-based radiopharmaceuticals in clinical settings.
NUCLIDIUM's Vision for the Future
NUCLIDIUM is dedicated to developing next-generation radiotherapeutics that utilize copper isotopes effectively. The focus remains on creating accessible and innovative cancer treatments tailored to meet the pressing needs of oncologists and patients alike. With a keen understanding of the hurdles faced in the oncology sector, NUCLIDIUM aims to bridge the gap by expanding the reach and effectiveness of radiopharmaceuticals.
About NUCLIDIUM AG
Operating from both Switzerland and Germany, NUCLIDIUM AG is at the forefront of biopharmaceutical innovation. The company's mission revolves around creating a new class of copper-based radiopharmaceuticals that stand out in their capability to enhance diagnostic and therapeutic options in cancer care. Through significant investments in research and collaborations, NUCLIDIUM is positioned to significantly influence the future of cancer treatment.
For more information, please contact:
NUCLIDIUM
Leila Jaafar, PhD, CEO
Email: info@nuclidium.com
Investor/Media Contact NUCLIDIUM
Trophic Communications
Stephanie May
Email: nuclidium@trophic.eu
Phone: +49 171 1855682
Frequently Asked Questions
What is the significance of the patent allowance for NUCLIDIUM?
The patent allowance enhances NUCLIDIUM's intellectual property position, potentially leading to better protection for its radiopharmaceutical innovations.
What technologies does NUCLIDIUM's Kalios™ program use?
Kalios™ utilizes copper radioisotopes, specifically Copper-61 for diagnostics and Copper-67 for therapeutic applications, targeting fibroblast activation protein.
How does FAP aid in cancer treatment?
FAP’s high expression in tumors allows for targeted diagnostics and therapies that improve the identification and treatment of cancers.
What are the advantages of NUCLIDIUM's copper-based agents?
The copper-based radiopharmaceuticals promise longer imaging capabilities and improved efficacy in targeting tumors compared to existing options.
Where is NUCLIDIUM based?
NUCLIDIUM operates primarily in Switzerland and Germany, emphasizing innovation in cancer treatment through advanced radiopharmaceutical technology.
